UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 1223, 2026

RAPID MICRO BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-40592	20-8121647
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
25 Hartwell Avenue, Lexington, MA		02421
(Address of principal executive offices)		(Zip Code)

978-349-3200

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbols

Name of each exchange on which
registered

Class A Common Stock, $0.01 par value per share

RPID

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On March 1223, 2026, Mr. John Wilson, Chief Operating Officer of Rapid Micro Biosystems, Inc. (the “Company”), ~~issued~~notified athe ~~press~~Company ~~release~~of ~~announcing~~his ~~its~~intention ~~financial~~to ~~results~~depart ~~for~~from ~~its~~the ~~its~~Company, ~~fourth~~effective ~~quarter~~April ~~and~~10, ~~fiscal~~2026, ~~year~~in ~~ended~~order ~~December~~to ~~31,~~spend ~~2025.~~more Atime ~~copy~~with ofhis ~~the~~family. ~~press~~Mr. ~~release~~Wilson’s departure is ~~attached~~not asthe ~~Exhibit~~result ~~99.1~~of toany ~~this~~disagreement ~~Current~~with ~~Report~~the Company on ~~Form~~any ~~8-K~~matter ~~and~~relating isto ~~incorporated~~the ~~herein~~Company’s byoperations, ~~reference~~policies inor ~~its entirety~~practices.

~~Item~~(c) 7In connection with Mr.01 Wilson’s anticipated departure, Mr. Robert Spignesi, the Company’s President and Chief Executive Officer, in addition to his current positions, will assume the role of the Company’s principal operating officer, effective April 10, 2026. The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation FDS-K ~~Disclosure~~related to Mr. Spignesi was previously disclosed in the Company’s definitive proxy statement filed on April 8, 2025. No material plan, contract or arrangement, nor any material amendment thereto, was entered into with Mr. Spignesi in connection with the foregoing event.

(e) On March 1226, 2026, the Company ~~issued~~entered into a ~~press~~Consulting Services and Separation Agreement (the “Agreement”) with Mr. Wilson. The Agreement provides for, among other things, a general release ~~announcing~~of claims in favor of the Company, certain separation benefits contained in the Employment Agreement, dated as of July 8, 2021, between the Company and Mr. Wilson, the material terms of which were summarized in the Company’s definitive proxy statement filed on April 8, 2025; the engagement of Mr. Wilson to provide certain advisory and other services to the Company on an hourly basis as a ~~new~~consultant, ~~multi-system~~at ~~order~~a ~~from~~rate ~~Samsung~~of ~~Biologics~~$200 per hour and not to exceed 20 hours per month, for ~~its~~a ~~Growth~~period ~~Direct~~of ~~platform~~time ending no later than June 30, 2026; an extension of the post-termination exercise period during which Mr. Wilson may exercise his vested stock options through March 31, 2027; and limits on the volume of shares per week of the Company’s Class A ~~copy~~common stock underlying such vested stock options that Mr. Wilson can sell, pledge, transfer, assign or otherwise dispose of during the ~~press~~same ~~release~~period is(subject ~~furnished~~to ~~herewith~~certain asexceptions ~~Exhibit~~described 99in the Agreement).2 ~~and~~The isAgreement ~~incorporated~~also ~~herein~~includes bycustomary ~~this~~provisions ~~reference~~regarding confidentiality, cooperation, non‑disparagement, return of Company property and other obligations.

The ~~information~~foregoing ~~furnished~~summary ~~under Items 2.02 and 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes~~ of ~~Section 18 of~~ the ~~Securities~~Agreement ~~Exchange~~does ~~Act~~not ofpurport ~~1934, as amended (the “Exchange Act”), or otherwise subject~~ to ~~the~~be ~~liabilities~~complete ofand ~~that~~is ~~section,~~qualified ~~nor~~in ~~shall~~its itentirety ~~be deemed incorporated~~ by reference into ~~any filing under~~ the ~~Securities~~full ~~Act~~text of ~~1933, as amended (~~the ~~"Securities Act")~~Agreement, orwhich ~~the~~is ~~Exchange~~filed ~~Act,~~as ~~except~~an asexhibit ~~otherwise~~to ~~expressly~~this ~~stated~~Current inReport ~~such~~on ~~filing~~Form 8‑K.


Item 9.01			Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press Release of Rapid Micro Biosystems, Inc., dated March 12, 2026, related to its financial results for its fourth quarter and fiscal year ended December 31, 2025.
10.1						Consulting Services and Separation Agreement, dated as of March 26, 2026, between the Company and John Wilson.
99.2						Press Release of Rapid Micro Biosystems, Inc., dated March 12, 2026
104						Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RAPID MICRO BIOSYSTEMS, INC.
Date: March 12, 2026	By:	/s/ Sean Wirtjes
Date: March 27, 2026	By:	/s/ Sean Wirtjes
		Sean Wirtjes
		Chief Financial Officer

Filing Compare · RAPID MICRO BIOSYSTEMS, INC.